Prediction of liver fibrosis in patients with chronic hepatitis B by serum markers

Hepato-Gastroenterology

Volumn 54, Issue 77, 2007, Pages 1503-1506

  Pan, Jen Jung ^a   Yang, Ching Fen ^a   Chu, Chi Jen ^a   Chang, Full Young ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Liver fibrosis; Platelet

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; THROMBOCYTE COUNT; UNIVARIATE ANALYSIS;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 34547613162     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
2. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30:956-961.
3. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32:477-481.
4. Maharaj B, Maharaj RJ, Leary WP, et al: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1:523-525.
5. Saadeh S, Cammell G, Carey WD, et al: The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33:196-200.
6. Andriulli A, Festa V, Leandro G, et al: Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Dig Dis Sci 2001; 46:1409-1415.
7. Fontana RJ, Lok AS: Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36:S57-S64.
8. Afdhal NH: Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37:972-974.
9. Ding H, Chen Y, Feng X, et al: Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Chung Hua Kan Tsang Ping Tsa Chih 2001; 9:78-80.
10. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
11. Renou C, Muller P, Jouve E, et al: Relevance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. Am J Gastroenterol 2001; 96:1657-1659.
12. Forns X, Ampurdanes S, Llovet JM, et al: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
13. Bonacini M, Hadi G, Govindarajan S, et al: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92:1302-1304.
14. Pohl A, Behling C, Oliver D, et al: Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96:3142-3146.
15. Poynard T, Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepatitis 1997; 4:199-208.
16. Wai CT, Greenson JK, Fontana RJ, et al: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
17. Matsumura H, Moriyama M, Goto I, et al: Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. J Viral Hepatitis 2000; 7:268-275.
18. Aster RH: Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1996; 45:645-657.
19. Koruk M, Onuk MD, Akcay F, et al: Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49:1645-1648.
20. Adinolfi LE, Giordano MG, Andreana A, et al: Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590-595.
21. Liaw YF, Lin DY, Chen TJ, et al: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9:235-241.
22. Williams AL, Hoofnagle JH: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95:734-739.
23. Giannini E, Botta F, Fasoli A, et al: Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44:1249-1253.
24. Sheth SG, Flamm SL, Gordon FD, et al: AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93:44-48.
25. Reedy DW, Loo AT, Levine RA: AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43:2156-2159.
26. Imperiale TF, Said AT, Cummings OW, et al: Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. [see comment]. Am J Gastroenterol 2000; 95:2328-2332.